VIDEO: Recent metastatic pancreatic cancer study ‘leaves us with many questions’
Click Here to Manage Email Alerts
In a video interview, Benjamin Schlechter, MD, talked about a “fascinating, compelling and important study” that looked at liposomal irinotecan injection regimen vs. nab-paclitaxel and gemcitabine in metastatic pancreatic cancer.
The irinotecan liposome injection regimen (Onivyde, Ipsen)— known as NALIRIFOX — prolonged OS compared with to nab-paclitaxel (Abraxane, Bristol Myers Squibb) and gemcitabine in metastatic pancreatic ductal adenocarcinoma, according to data presented at ASCO Gastrointestinal Cancers Symposium. However, Schlechter, of Dana-Farber Cancer Institute, said “it’s not the simplest data to interpret because NALIRIFOX is not FOLFIRINOX and we don’t have a head-to-head comparison of liposomal irinotecan vs. conventional irinotecan.
“I think the reality is that we don’t know if this is better than FOLFIRINOX or modified FOLFIRINOX, but we do know that this is a substantially more expensive regimen,” he continued. “So, I think that we need to sort out reutilization perspective, whether this is better or just kind of fancier.”
Schlechter also noted it’s unclear how this impacts the standard of care in the first-line therapy of metastatic pancreatic cancer.
“It’s a positive trial — it was a well-done, very compelling study — but I think it leaves us with many questions about the role of FOLFIRINOX and the place of [gemcitabine nab-paclitaxel],” he said.
Reference:
- Wainberg ZA, et al. Abstract LBA661. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 19-21, 2023; San Francisco.
Collapse
Healio Interview
Click Here to Manage Email Alerts